Skip to content

Effect of different transcranial magnetic stimulation protocols on cognitive function in patients with post-stroke cognitive impairment

Effect of different transcranial magnetic stimulation protocols on cognitive function in patients with post-stroke cognitive impairment: an exploratory single-center randomized double-blind controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064233
Enrollment
Unknown
Registered
2022-09-30
Start date
2023-09-21
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke cognitive impairment

Interventions

Group B :Intermittent Theta Burst Transcranial Magnetic Stimulation

Sponsors

Zhujiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for stroke as defined by the 4th National Academic Conference on Cerebrovascular Diseases in 1995 and confirmed by CT or MRI of the head. 2. First attack, unilateral lesion, duration of disease between 3-12 months. 3. Right-handedness. 4. Aged 18-80 years. 5. Cognitive impairment (total score <= 24) as assessed by the Montreal cognitive assessment (MoCA). 6. No severe aphasia and able to complete cognitive tests. 7. Stable vital signs and no progression of neurological symptoms 8. Normal cognitive function prior to stroke. 9. Voluntary participation and signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of previous stroke. 2. CT/MRI confirmed complete damage to the left prefrontal cortex. 3. Bilateral brain lesions. 4. Previous transcranial surgery or current presence of a cranial defect. 5. Ongoing use of antidepressants or neuroleptics. 6. Metal implants or pacemakers in close proximity to the treatment site. 7. Previous other brain disorders such as brain tumours, traumatic brain injury, seizures, etc. 8. History of malignancy. 9. Failure of vital organs. 10. Any neuropsychiatric comorbidities and affective disorders that may affect the test results. 11. Any other factors that may affect cognitive assessment and treatment.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment;

Secondary

MeasureTime frame
rest electroencephalogram;Auditory Verb Learning Test;Symbol Digit Modalities Test;Digital Span Test;

Countries

China

Contacts

Public ContactKang-lin Wang

Zhujiang Hospital of Southern Medical University

wkangling@126.com+86 159 8920 1852

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 19, 2026